Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Continuing Education
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Continuing Education
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
Research ArticleBrief Communication

Six of 12 Relapsed or Refractory Indolent Lymphoma Patients Treated 10 Years Ago with 131I-Tositumomab Remain in Complete Remission

Franz Buchegger, Cristian Antonescu, Claudine Helg, Marek Kosinski, John O. Prior, Angelika Bischof Delaloye, Oliver W. Press and Nicolas Ketterer
Journal of Nuclear Medicine June 2011, 52 (6) 896-900; DOI: https://doi.org/10.2967/jnumed.111.087460
Franz Buchegger
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cristian Antonescu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claudine Helg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marek Kosinski
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John O. Prior
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Angelika Bischof Delaloye
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Oliver W. Press
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicolas Ketterer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

The purpose of our study was to update the safety and efficacy results of radioimmunotherapy in relapsed or resistant indolent or transformed non-Hodgkin lymphoma. Methods: More than 9 y ago, we treated 12 indolent and 4 transformed, relapsed or refractory lymphoma patients with a single administration of nonmyeloablative therapy with tositumomab and 131I-tositumomab. The 16 patients had a mean of 3.1 (range, 1–6) previous chemotherapy and antibody treatments. Results: Six of 12 relapsed indolent lymphoma patients remain disease-free a mean of 9.8 y (range, 8.6–10.7 y) after radioimmunotherapy. Three of 4 transformed lymphoma patients progressed after radioimmunotherapy, and 1 patient had a partial response of 10 mo. Conclusion: Optimal patient benefit might be obtained in indolent lymphoma when administering radioimmunotherapy up-front in combination with chemotherapy and rituximab treatment. However, these results show that radioimmunotherapy alone achieved long-lasting remissions in 6 of 12 (50%) indolent lymphoma patients in relapse after 1 or multiple chemotherapies.

  • 131I-tositumomab
  • radioimmunotherapy
  • long-term efficacy

Advanced-stage indolent or follicular non-Hodgkin lymphoma (NHL) is considered incurable by conventional therapy. Only localized stage I or II follicular lymphoma may occasionally be cured with radiotherapy of involved sites (1). These authors stated: “patients who remain disease-free 10 years after [radiotherapy] are unlikely to relapse.”

Two commercial antibodies targeting the CD20 antigen, 131I-tositumomab and 90Y-ibritumomab, and other radiolabeled antibodies in research trials have been shown to lead to high percentages of complete remissions (CRs) (2,3) and long-lasting responses either up-front (4) or at recurrence after chemotherapy (5–9). Radioimmunotherapy is a combination of radiotherapy and antibody treatment. The use of a 131I-labeled antibody may have the clinical advantage that the low-energy electrons emitted by this radioisotope appear well adapted for treatment of minimal disease (10,11) and 131I therapy of thyroid cancer is well tolerated (12).

A high percentage of complete response was reported for 41 relapsed patients treated in England with tositumomab and 131I-tositumomab in the same protocol (5). As a second European center participating in this multicenter study, otherwise mainly conducted in the United States, we report the 10-y update from Switzerland for 16 patients who experienced a particularly high long-term efficacy of 131I-tositumomab.

MATERIALS AND METHODS

Sixteen patients (Table 1) were treated in Switzerland between August 1999 and November 2001 in the frame of this single-arm, open-label phase II study of Corixa Corp. and GlaxoSmithKline. The protocol aimed at establishing the response rate, duration of response, safety, and survival after 131I-tositumomab radioimmunotherapy in patients with indolent or transformed B-cell lymphoma after first or multiple recurrences or resistance to treatment. The study protocol was approved by the local Ethics Committees of the University Hospitals of Lausanne and Geneva, the Intercantonal Drug Control Office (later renamed Swissmedic), and the Swiss Federal Office of Public Health, Section of Radioprotection.

View this table:
  • View inline
  • View popup
TABLE 1

Characteristics of Patients with Indolent or Transformed Lymphoma at Radioimmunotherapy

Eligibility criteria were as described for patients having given written informed consent (13). The most salient criteria were an indolent, CD20-positive B-cell lymphoma confirmed by histology, in relapse or resistant after at least 1 full regimen of chemotherapy. Maximal acceptable lymphoma infiltration of bone marrow (trephine biopsy) was 25%. Patients having had high-dose chemotherapy or radiotherapy, including stem cell rescue, were excluded.

Dosimetry and Therapy

Tositumomab and 131I-tositumomab were provided by the study sponsor. Tositumomab 131I-labeling was performed centrally (MDS Nordion Inc.) and was shipped frozen. Patient preparation included thyroid blocking (2 × 100 mg of potassium iodide daily orally from 2 d before dosimetry to 14 d after radioimmunotherapy) and premedication with 500 mg of paracetamol and 2 mg of clemastine orally before antibody administration. For dosimetry, patients received 450 mg of unlabeled tositumomab followed by 35 mg of 131I-tositumomab (185 MBq). After repeated whole-body scintigraphy (14), the 131I-tositumomab therapeutic activity was calculated (14) to deliver a whole-body dose of 75 or 65 cGy for patients with normal or reduced platelet counts, respectively. Therapy, consisting of the infusion of 450 mg unlabeled tositumomab followed by 35 mg of 131I-tositumomab (2,867 ± 454 MBq), was performed within 2 wk from dosimetry.

Response and Evaluation of Side Effects

Responses were evaluated (including physical examination, CT, and bone marrow biopsy if bone marrow was involved before treatment) according to the 1999 International Working Group criteria, and evaluations were performed at weeks 13 and 26 and every 6 mo thereafter until disease progression. Progression-free survival (PFS) was defined as the time from treatment initiation to first documentation of progression or death and overall survival (OS) as the time from treatment start to death. Subjects were censored at the time of the last evaluation if they did not experience an event.

All adverse events from study entry through week 13 and adverse events after this period possibly or probably related to therapy were graded according to the National Cancer Institute Common Toxicity Criteria. Detailed blood analysis was performed weekly from study week 3 to 9 or until recovery and repeated at weeks 13 and 26 and every 6 mo thereafter. Other toxicity evaluations included blood chemistry and thyroid-stimulating hormone assays for all patients every 6 mo. The HAMA (human antimouse IgG antibody) assay (HAMA Elisa; Medac) performed for all patients had to be negative at inclusion. The HAMA assay was repeated at weeks 7, 13, and 26 after therapy and every 6 mo thereafter. Long-term evaluations after 2 y from treatment were performed every 6 mo.

Statistical Analysis

PFS and OS were analyzed using the Kaplan–Meier survival analysis, and differences among patient subgroups were tested with the log-rank test using Stata 11.1 (StataCorp). P values of less than 0.05 were considered significant.

RESULTS

Response to Radioimmunotherapy

All patients—8 with CR/unconfirmed complete response (CRu) and 4 with partial response (PR)—treated for relapsed indolent lymphoma responded. For PR patients, the duration of response was 0.5–1.4 y (Fig. 1A). Three PR patients survived 1.3–5.2 y, and 1 patient remains alive after 10 y.

FIGURE 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1.

Kaplan–Meier plots in years showing OS (solid line) and PFS (dashed line) of patients who presented with relapsed indolent lymphoma (A) and 4 patients with transformed disease (B). Tics indicate censored data.

The 8 patients experiencing CR/CRu had a mean of 2.5 chemotherapy or rituximab treatments before radioimmunotherapy, 2 patients had radiotherapy, and 1 patient had interferon-α treatment (Table 1). More specifically, 7 patients (88%) had received anthracycline, 6 (75%) an alkylating agent, and 5 (63%) rituximab. Two patients (25%) had elevated lactate dehydrogenase, and 7 (88%) had bulky tumor.

One CR patient had a relapse after 28 mo, but OS has continued, lasting currently 10 y. Another CRu patient developed secondary myelodysplastic syndrome (MDS) and subsequent leukemia (acute myeloid leukemia [AML]) 2.8 y after radioimmunotherapy and 6.2 y after cyclophosphamide, hydroxydaunorubicin, Oncovin, and prednisone (CHOP). Today, 6 of 12 CR/CRu patients (50%) remain disease free, a mean of 9.8 y (range, 8.6–10.7 y) after radioimmunotherapy (Fig. 1A).

Among 4 patients with transformed lymphoma, disease progression after radioimmunotherapy was observed in 3 (Fig. 1B), whereas 1 patient responded with a PR that lasted 10 mo, OS being longer than 10.5 y.

PFS and OS differences between indolent and transformed disease were significant (P < 0.0001 and P < 0.03, respectively). Median PFS and OS for indolent lymphoma (n = 12) are 8.6 y or more and 8.8 y or more (50% events not reached), respectively, whereas for transformed disease (n = 4) they were 0.2 and 0.8 y, respectively. Given the small number of patients, these statistics must be considered cautiously.

Adverse Events

All treated patients experienced transient bone marrow depression. Bone marrow depression was grade 1 or 2 (minor) in 4 patients and grade 3 or 4 in 12 patients. Twenty-eight nonhematologic side effects, mostly mild (25 grade 1 or 2), were reported for 9 patients. These side effects included pain, fatigue, fever, chills, sweating, rash, arthralgia, erythema, and edema; 1 case of pneumonia, 1 of thyroiditis; and 1 of elevated TSH (without hormone replacement). Four patients developed HAMA. One case of febrile lymphadenitis during pancytopenia and 1 of febrile neutropenia, both grade 3, observed 7–8 wk after radioimmunotherapy, resolved rapidly after the administration of antibiotics.

One patient experienced an MDS 2.8 y after radioimmunotherapy, that is, 6.2 y after initial diagnosis and treatment with 5 cycles of CHOP. He died subsequently from leukemia.

DISCUSSION

In stage I or II follicular lymphoma treated with radiotherapy, a reduced probability of tumor recurrence was observed after 10 y of recurrence-free survival. Only 5 of 47 patients (11%) relapsed after 10 y (1). Radioimmunotherapy comprises systemic, targeted radiotherapy combined with immunotherapy. Thus, it is tempting to compare the situation of the 6 indolent lymphoma patients without recurrence 9.8 y after radioimmunotherapy with the low relapse probability that was observed after 10 y of recurrence-free survival after initial radiotherapy (1).

We observed a high percentage of long-lasting CR after radioimmunotherapy without concomitant chemotherapy or maintenance treatment. These results compare favorably with long-term observations after 131I-tositumomab treatment in the literature (9,15) and are similar to the results of combined chemotherapy and radioimmunotherapy in the initial treatment of follicular lymphoma (16). Combined up-front treatment including chemotherapy or rituximab–chemotherapy and radioimmunotherapy for consolidation (16,17) and further maintenance immunotherapy might provide optimal patient benefit. The South West Oncology Group (US) phase II trial (NCT00770224) is currently exploring this strategy. Radioimmunotherapy alone, however, was able to bring patients—even after multiple chemotherapy relapses—into particularly long-lasting CR.

One of our patients experienced MDS. As was shown by large cohort studies, the incidence of secondary MDS or AML was not increased after radioimmunotherapy, as compared with conventional therapies (3,18). Alkylating agents and doxorubicin (CHOP constituents) are, however, known to increase the risk for MDS or AML (19). Globally, an estimated 10% of treated lymphoma patients will develop secondary MDS or AML within 10 y (19).

A high efficacy of radioimmunotherapy with 90Y-ibritumomab has been reported repeatedly (3,8,17), including a report on 5-y relapse-free survival in close to 20% of patients with recurrent disease (20). However, 10-y observations after 90Y-ibritumomab radioimmunotherapy are not yet available. At our institution, one of the first patients treated has reached a current 9-y survival without objective recurrence after 90Y-ibritumomab radioimmunotherapy consolidation. Theoretically, the low-energy electrons emitted by 131I could be better adapted than the high-energy electrons of 90Y to eradicate minimal disease. Also, tositumomab is different from the chimeric antibody rituximab, the latter having been derived from the mouse antibody ibritumomab. In patients who have been or are treated with rituximab, the use of a different antibody in radioimmunotherapy could be an advantage. In the absence of a direct comparison between 90Y-ibritumomab and 131I-tositumomab, however, speculations on the advantages of one compared with the other radioimmunotherapy remain theoretic.

Our results could be the result of a favorable coincidence because we treated a small patient population. The 6 patients observed in continued CR close to 10 y after radioimmunotherapy alone, however, are remarkable. In another recent report on 60 patients, including 36 patients with relapsed or resistant low-grade lymphoma, 12 patients responded with CR and 5 remain in continued CR at 10 y or more after radioimmunotherapy (15). In a different interpretation, our small series of patients could reflect a better efficacy of 131I-tositumomab in a European subpopulation with disease characteristics different from those of U.S. patients or of patients who have had a different treatment history. The high CR rate reported for England for the same study (5) was also higher than what is generally reported for this therapy in the United States. The authors of that study reported a 53% CR/CRu rate for recurrent or resistant indolent lymphoma (5). These hypotheses cannot currently be confirmed because 131I-tositumomab has not been studied comparatively between Europe and the United States, and large patient groups overall have not yet been treated with 131I-tositumomab in Europe.

CONCLUSION

These results show a particularly high number of CR/CRu in recurrent indolent NHL. We observed exceptionally long-lasting PFS, with 6 ongoing CRs after a mean of 9.8 y after radioimmunotherapy, representing half of the indolent, relapsed lymphoma patients. Toxicity was mild or transient, except for 1 patient who developed a secondary MDS. Previous reports have shown that a significant number of indolent, relapsed NHL patients experience CR under radioimmunotherapy. Here, 6 of 12 patients treated with radioimmunotherapy alone reached a close to 10 y of relapse-free survival, and relapse probability in the next few years may expectedly be small for these patients.

DISCLOSURE STATEMENT

The costs of publication of this article were defrayed in part by the payment of page charges. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734.

Acknowledgments

We acknowledge support from the Swiss Cancer League KFS 991-02-2000. We express our gratitude to Frances Godson for reviewing the manuscript and to the referring physicians, Drs. Alfonso Zaccaria, Ravenna, Italy; Jean-Philippe Grob, Lausanne, Switzerland; Pierre Hösli, Yverdon-les-Bains, Switzerland; Christian De Pree, Geneva, Switzerland; and Christian Taverna and Alexander Knuth, Zurich, Switzerland. OWP declared an honorarium from Spectrum Pharmaceuticals.

  • © 2011 by Society of Nuclear Medicine

REFERENCES

  1. 1.↵
    1. Mac Manus MP,
    2. Hoppe RT
    . Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol. 1996;14:1282–1290.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Kaminski MS,
    2. Estes J,
    3. Zasadny KR,
    4. et al
    . Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood. 2000;96:1259–1266.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Witzig TE,
    2. White CA,
    3. Gordon LI,
    4. et al
    . Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol. 2003;21:1263–1270.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Kaminski MS,
    2. Tuck M,
    3. Estes J,
    4. et al
    . 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005;352:441–449.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Davies AJ,
    2. Rohatiner AZ,
    3. Howell S,
    4. et al
    . Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2004;22:1469–1479.
    OpenUrlAbstract/FREE Full Text
  6. 6.
    1. Horning SJ,
    2. Younes A,
    3. Jain V,
    4. et al
    . Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol. 2005;23:712–719.
    OpenUrlAbstract/FREE Full Text
  7. 7.
    1. Leahy MF,
    2. Turner JH
    . Radioimmunotherapy of indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year, single institution experience of 142 consecutive patients. Blood. 2011;117:45–52.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Pisani F,
    2. Maini CL,
    3. Sciuto R,
    4. et al
    . FCR (fludarabine, cyclophosphamide, rituximab) regimen followed by 90yttrium ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma: a report of 9 cases. J Exp Clin Cancer Res. 2011;30:16.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Fisher RI,
    2. Kaminski MS,
    3. Wahl RL,
    4. et al
    . Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol. 2005;23:7565–7573.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Sharkey RM,
    2. Weadock KS,
    3. Natale A,
    4. et al
    . Successful radioimmunotherapy for lung metastasis of human colonic cancer in nude mice. J Natl Cancer Inst. 1991;83:627–632.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Vogel CA,
    2. Galmiche MC,
    3. Buchegger F
    . Radioimmunotherapy and fractionated radiotherapy of human colon cancer liver metastases in nude mice. Cancer Res. 1997;57:447–453.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Hall P,
    2. Boice JD Jr.,
    3. Berg G,
    4. et al
    . Leukaemia incidence after iodine-131 exposure. Lancet. 1992;340:1–4.
    OpenUrlPubMed
  13. 13.↵
    1. Buchegger F,
    2. Antonescu C,
    3. Delaloye Bischof A,
    4. et al
    . Long-term complete responses after 131I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma. Br J Cancer. 2006;94:1770–1776.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Wahl RL,
    2. Kroll S,
    3. Zasadny KR
    . Patient-specific whole-body dosimetry: principles and a simplified method for clinical implementation. J Nucl Med. 1998;39(8, suppl):14S–20S.
    OpenUrlPubMed
  15. 15.↵
    1. Kaminski MS,
    2. Zelenetz AD,
    3. Press OW
    . Tositumomab and I 131 tositumomab achieves complete remissions lasting > 10 years in patients with chemotherapy-refractory low grade and transformed B-cell lymphomas. Paper presented at: 52nd ASH annual meeting and exposition; December 4–7, 2010; Orlando, FL.
  16. 16.↵
    1. Martin P,
    2. Coleman M,
    3. Furman RR,
    4. et al
    . Fludarabine plus I-131 tositumomab as initial treatment for follicular lymphoma: half of patients in remission at over 10 years median followup. Paper presented at: 52nd ASH annual meeting and exposition; December 4–7, 2010; Orlando, FL.
  17. 17.↵
    1. Morschhauser F,
    2. Radford J,
    3. Van Hoof A,
    4. et al
    . Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol. 2008;26:5156–5164.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Bennett JM,
    2. Kaminski MS,
    3. Leonard JP,
    4. et al
    . Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood. 2005;105:4576–4582.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Armitage JO,
    2. Carbone PP,
    3. Connors JM,
    4. Levine A,
    5. Bennett JM,
    6. Kroll S
    . Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol. 2003;21:897–906.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Witzig TE,
    2. Molina A,
    3. Gordon LI,
    4. et al
    . Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer. 2007;109:1804–1810.
    OpenUrlCrossRefPubMed
  • Received for publication January 5, 2011.
  • Accepted for publication February 18, 2011.
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 52 (6)
Journal of Nuclear Medicine
Vol. 52, Issue 6
June 1, 2011
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Six of 12 Relapsed or Refractory Indolent Lymphoma Patients Treated 10 Years Ago with 131I-Tositumomab Remain in Complete Remission
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Six of 12 Relapsed or Refractory Indolent Lymphoma Patients Treated 10 Years Ago with 131I-Tositumomab Remain in Complete Remission
Franz Buchegger, Cristian Antonescu, Claudine Helg, Marek Kosinski, John O. Prior, Angelika Bischof Delaloye, Oliver W. Press, Nicolas Ketterer
Journal of Nuclear Medicine Jun 2011, 52 (6) 896-900; DOI: 10.2967/jnumed.111.087460

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Six of 12 Relapsed or Refractory Indolent Lymphoma Patients Treated 10 Years Ago with 131I-Tositumomab Remain in Complete Remission
Franz Buchegger, Cristian Antonescu, Claudine Helg, Marek Kosinski, John O. Prior, Angelika Bischof Delaloye, Oliver W. Press, Nicolas Ketterer
Journal of Nuclear Medicine Jun 2011, 52 (6) 896-900; DOI: 10.2967/jnumed.111.087460
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE STATEMENT
    • Acknowledgments
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • Characteristic Comparison Between 131I-Interferon-{alpha} and 131I-Interferon-{alpha}-Immunoglobulin-Fc Hybrid Protein in Rats Using Molecular Imaging
  • Google Scholar

More in this TOC Section

  • [177Lu]Lu-PSMA-617 Therapy in a Patient with Chronic Kidney Disease
  • Radiation Safety Considerations of Household Waste Disposal After Release of Patients Who Have Received [177Lu]Lu-PSMA-617
  • The Diagnostic Value of the Sentinel Node Procedure to Detect Occult Lymph Node Metastases in PSMA PET/CT Node–Negative Prostate Cancer Patients
Show more BRIEF COMMUNICATION

Similar Articles

SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire